Key facts
- It has raised $14.5M; the latest was Seed Round ($14.5M) in Mar 2026.
- Notable investors include YuanBio Venture Capital, Lapam Capital, Yijing Capital, Chaosheng Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Maibozhixing
- ·The full record, as it builds
Funding rounds
No funding rounds for Maibozhixing are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Maibozhixing
Manufacturer of antibody-based therapeutics designed to treat inflammation and autoimmune diseases. The company offers antibody engineering and AI-driven discovery capabilities, enabling biopharmaceutical research and clinical development teams to enhance candidate quality and accelerate the development of globally relevant therapeutic antibodies.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2025
- Ownership
- Privately Held (backing)
Maibozhixing doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Maibozhixing shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Maibozhixing in its N-PORT filings yet. We sweep new filings monthly.